Atlantis Medical News
Technology for a better future
Undoubtedly, what is important is the health of each and every patient. Nowadays, technology can complete a lot of actions and calculations that humans are not able to do, the NHS (National Health service) tend to complete modern experiments to utilise the technological world and use it to tackle one of the biggest worries of our world: human health.
With a new idea came more investors. This big idea was launched by Elizabeth Holmes, founder of Theranos. The Silicon Valley start-up claimed to have developed a new, cheaper blood testing technology and convinced enough investors to raise more than US $400m. At its height in 2014, the company was valued at US$9bn and its founder’s personal worth at $4.5bn. Rupert Murdoch was one of its investors. In 2015, Ms Holmes was personally praised by both the then-US President Barack Obama and vice-president Joe Biden. Last month, the company was formally dissolved as it was discovered that the technology didn’t work. US prosecutors are pursuing criminal charges against Ms Holmes for defrauding investors of hundreds of millions of dollars.
The harm caused to patients in misdiagnosis, to unnecessary operations arising from the company’s erroneous blood tests has yet to be quantified. The quality of care must be the focus for delivering out care with respect and dignity, meaning we must focus on having a commitment to quality of care, compassion and provide respect and dignity to improve the lives of patients. This can mean putting the patient’s needs, as they define them, above those identified as priorities by healthcare professionals. These are the few respective measures taken as an oath by the NHS members. Hopefully, things will be put in place to get the NHS the correct equipment for a better future. The right way to provide an essential health service is through using medical technology that will serve the human era with less effort and better comfort, to address the unique physiological, safety, self-esteem and self-actualization needs in each client’s individualised plan of home healthcare.
The UK is making dreams come true through the help of the brilliant minds of the students studying and researching the technological support for medical science as there is high service demand for this in the real world. Right now, the NHS is approving those technologies that are presented with worthy evidence to decrease the risk factors before getting them implanted for the experiment on their respective patients.
Dr Topol’s review, expected by the end of the year, could place more immediate extra pressure for better evidence before deploying new technology. But it also might not. It the meantime, the best defence against a Theranos like scandal in the NHS is a healthy scepticism for unproven technology at every level of the system.